How I treat hairy cell leukemia

Blood

Volumn 115, Issue 1, 2010, Pages 21-28

  Grever, Michael R ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD103 ANTIGEN; CD123 ANTIGEN; CD20 ANTIGEN; CLADRIBINE; GLYCOPROTEIN P 15095; INTERLEUKIN 2 RECEPTOR ALPHA; PENTOSTATIN; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB;

ARTICLE; BONE MARROW BIOPSY; CONTINUOUS INFUSION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; FLOW CYTOMETRY; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA RELAPSE; LIFE EXPECTANCY; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; SPLENECTOMY; TREATMENT RESPONSE; DRUG RESISTANCE; PATHOLOGY; RECURRENT DISEASE; REVIEW;

DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, HAIRY CELL; RECURRENCE;

EID: 74949122021     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-195370     Document Type: Article

References (72)

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7): 609-630.
2. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med. 1984;310(1):15-18.
3. Spiers AS, Parekh SJ, Bishop MB. Hairy-cell leukemia: induction of complete remission with pentostatin (2′-deoxycoformycin). J Clin Oncol. 1984; 2(12):1336-1342.
4. Kraut EH, Bouroncle BA, Grever MR. Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood. 1986;68(5):1119-1122.
5. Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood. 1994; 84(12):4061-4063.
6. Johnston JB, Eisenhauer E, Corbett WE, Scott JG, Zaentz SD. Efficacy of 2′-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst. 1988;80(10):765-769.
7. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13(4):974-982.
8. Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients: a French retrospective study of 238 patients. Leukemia. 2003;17(1): 45-51.
9. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322(16):1117-1121.
10. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92(6):1918- 1926.
11. Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood. 1992;80(9):2203-2209.
12. Lauria F, Bocchia M, Marotta G, Raspadori D, Zinzani PL, Rondelli D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica. 1999;84(1):22-25.
13. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J Clin Oncol. 1997;15(3):1138-1142.
14. Jehn U, Gawaz M, Grunewald R, Hill W, Lorenz B, Stotzer O. Successful treatment of patients with hairy cell leukemia (HCL) using a single cycle of 2-chloro-2′-deoxyadenosine (CdA). Anticancer Res. 1993;13(5C):1809-1814.
15. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005;106(1):241-246.
16. Johnston JB, Eisenhauer E, Wainman N, Corbett WE, Zaentz SD, Daeninck PJ. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin Oncol. 2000; 27[suppl 5]:32-36.
17. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000; 96(9):2981-2986.
18. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733-740.
19. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21(5):891-896.
20. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733-740.
21. Sharpe RW, Bethel KJ. Hairy cell leukemia: diagnostic pathology. Hematol Oncol Clin North Am. 2006;20(5):1023-1049.
22. Tallman MS, Hakimian D, Kopecky KJ, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res. 1999;5(7):1665-1670.
23. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006;107(12):4658-4662.
24. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer. 2005;104(11):2442-2448.
25. Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, et al. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med. 2006;130(3):374-377.
26. Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia. 2001;15(1):184-186.
27. Golomb HM. Hairy cell leukemia: lessons learned in twenty-five years. J Clin Oncol. 1983;1(10): 652-656.
28. Krause JR. Aplastic anemia terminating in hairy cell leukemia: a report of two cases. Cancer. 1984;53(7):1533-1537.
29. Gillis S, Amir G, Bennett M, Polliack A. Unexpectedly high incidence of hypoplastic/aplastic foci in bone marrow biopsies of hairy cell leukemia patients in remission following 2-chlorodeoxyadenosine therapy. Eur J Haematol. 2001;66(1):7-10.
30. Matutes E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20(5):1051-1063.
31. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004;363(9424):1869-1870.
32. Jansen J, Hermans J. Clinical staging system for hairy-cell leukemia. Blood. 1982;60(3):571-577.
33. Arons E, Sunshine J, Suntum T, Kreitman RJ. Somatic hypermutation and VH gene usage in hairy cell leukaemia. Br J Haematol. 2006;133(5): 504-512.
34. Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ. Soluble CD22 as a tumor marker for hairy cell leukemia. Blood. 2008;112(6):2272-2277.
35. Forconi F, Poretti G, Kwee I, et al. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. Br J Haematol. 2008;141(5):622-630.
36. Forconi F, Sozzi E, Rossi D, et al. Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. Haematologica. 2008;93(5):697-705.
37. Barak V, Nisman B, Polliack A, Vannier E, Dinarello CA. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia. Eur Cytokine Netw. 1998;9(1):33-39.
38. Chrobak L, Podzimek K, Pliskova L, et al. Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia. Neoplasma. 1996;43(5):321-325.
39. Hoffman MA. Clinical presentations and complications of hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20(5):1065-1073.
40. Damaj G, Kuhnowski F, Marolleau JP, Bauters F, Leleu X, Yakoub-Agha I. Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients. Eur J Haematol. 2009;83(3):246-250.
41. Kraut EH, Neff JC, Bouroncle BA, Gochnour D, Grever MR. Immunosuppressive effects of pentostatin. J Clin Oncol. 1990;8(5):848-855.
42. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med. 1994;120(9):784-791.
43. Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994;83(10):2906-2911.
44. Ravandi F, O'Brien S. Infections associated with purine analogs and monoclonal antibodies. Blood Rev. 2005;19(5):253-273.
45. Ventura F, Rocha J, Pereira T, Marques H, Pardal F, Brito C. Sweet syndrome as the presenting symptom of hairy cell leukemia. Dermatol Online J. 2009;15(2):12.
46. Viens D, St-Hilaire E, Beauregard P, Dufresne J, Knecht H. Successful treatment of warm antibody (IgG/C3 positive) autoimmune hemolytic anemia in hairy-cell leukemia with 2-CdA in the elderly. Leuk Lymphoma. 2008;49(7):1424-1426.
47. Vankalakunti M, Joshi K, Jain S, Nada R, Radotra BD, Varma S. Polyarteritis nodosa in hairy cell leukaemia: an autopsy report. J Clin Pathol. 2007;60(10):1181-1182.
48. Kilbridge TM, Kadin ME. Teenager with hairy cell leukemia: 30-year follow-up. J Clin Oncol. 2009; 27(1):155-156.
49. Hisada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst. 2007; 99(3):215-222.
50. Gedik E, Girgin S, Aldemir M, Keles C, Tuncer MC, Aktas A. Non-traumatic splenic rupture: report of seven cases and review of the literature. World J Gastroenterol. 2008;14(43):6711-6716.
51. Szotkowski T, Szotkowska R, Pikalova Z, et al. Spontaneous splenic rupture in two patients with hematologic malignancy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007; 151(1):113-116.
52. Swords R, Giles F. Hairy cell leukemia. Med Oncol. 2007;24(1):7-15.
53. Golomb HM. Hairy cell leukemia: treatment successes in the past 25 years. J Clin Oncol. 2008; 26(16):2607-2609.
54. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007;109(9):3672-3675.
55. Belani R, Saven A. Cladribine in hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20(5): 1109-1123.
56. Grever MR. Pentostatin: impact on outcome in hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20(5):1099-1108.
57. Juliusson G, Liliemark J. Purine analogues: rationale for development, mechanisms of action, and pharmacokinetics in hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20(5):1087-1097.
58. Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica. 2004;89(3):309-313.
59. Zenhausern R, Schmitz SF, Solenthaler M, et al. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma. 2009:1-11.
60. Estey EH, Kurzrock R, Kantarjian HM, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood. 1992; 79(4):882-887.
61. Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood. 1992;79(4): 888-894.
62. Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood. 1999; 93(8):2471-2477.
63. Benz R, Siciliano RD, Stussi G, Fehr J. Longterm follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia. Eur J Haematol. 2009;82(3):194-200.
64. Thomas DA, Ravandi F, Kantarjian H. Monoclonal antibody therapy for hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20(5):1125-1136.
65. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer. 2007;110(10):2240-2247.
66. Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev. 2006;32(5):365-376.
67. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105(1):49-53.
68. Quigley MM, Bethel KJ, Sharpe RW, Saven A. CD52 expression in hairy cell leukemia. Am J Hematol. 2003;74(4):227-230.
69. Lauria F, Raspadori D, Benfenati D, Rondelli D, Pallotti A, Tura S. Biological markers and minimal residual disease in hairy cell leukemia. Leukemia. 1992;6[suppl 4]:149-151.
70. Kreitman RJ, Pastan I. Immunotoxins in the treatment of refractory hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20(5):1137-1151.
71. Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs. 2009; 23(1):1-13.
72. Habermann TM. Splenectomy, interferon, and treatments of historical interest in hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20(5): 1075-1086.